Anesiva, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1999-01-01
- Employees
- 100
- Market Cap
- -
- Website
- http://anesiva.com
Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department
- Conditions
- Intravenous Placement Procedure
- Interventions
- Behavioral: Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00766181
Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement
- Conditions
- Arthroplasty
- Interventions
- Drug: PlaceboDrug: 4975, highly purified capsaicin
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2009-05-04
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT00683267
- Locations
- 🇺🇸
University of California at San Francisco - Mt. Zion, San Francisco, California, United States
🇺🇸Webster Orthopaedic Medical Group, Oakland, California, United States
🇺🇸Coastal Medical Research, Inc., Port Orange, Florida, United States
Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement
- Conditions
- Total Knee Arthroplasty (Replacement)
- Interventions
- Drug: 4975 - 5 mgDrug: Placebo ComparatorDrug: 4975, 15 and 5 mg
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2009-05-04
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00681356
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Miami Institute for Medical Research, Miami, Florida, United States
🇺🇸Memorial City Hospital - Memorial Hermann Healthcare System, Houston, Texas, United States
Safety and Tolerability of 4975 in Patients Undergoing Arthroscopic Surgery to Repair the Rotator Cuff of the Shoulder
- Conditions
- Rotator Cuff Repair of the Shoulder
- Interventions
- Drug: 4975 - Highly purified capsaicinDrug: Placebo
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2009-05-04
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00672568
- Locations
- 🇰🇷
Gyeongsang National University Hospital, Jinju, Kyungsangnamdo, Korea, Republic of
🇰🇷Kangnam St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
🇰🇷Kyungpook National university Hospital, Daegu, Jung-gu, Korea, Republic of
Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy
- Conditions
- Pain
- Interventions
- Drug: 4975Drug: Placebo
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2009-05-04
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00656578
- Locations
- 🇺🇸
Foot and Ankle Institute, Bakersfield, California, United States
🇺🇸Scirex Research Center, Salt Lake City, Utah, United States
🇺🇸Crossroads Research, Inc., Owings Mills, Maryland, United States
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00125333
- Locations
- 🇺🇸
University of Miami Skin Research, Miami, Florida, United States
🇺🇸Helendale Dermatology & Medical Spa, LLP, Rochester, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
- Conditions
- Chronic Renal FailureHyperplasia
- First Posted Date
- 2004-06-29
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Anesiva, Inc.
- Registration Number
- NCT00086164
- Locations
- 🇺🇸
Thoracic & Cardiovascular Healthcare Foundation, Lansing, Michigan, United States
🇺🇸St. Luke's Hospital, Department of Surgery, New York, New York, United States
🇺🇸Outcomes Research International, Inc., Hudson, Florida, United States
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2002-07-24
- Last Posted Date
- 2006-05-05
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT00042081
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Presbyterian Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
- Conditions
- HyperplasiaArterial Occlusive DiseasesPeripheral Vascular DiseasesIschemiaGraft Occlusion, Vascular
- First Posted Date
- 2002-07-22
- Last Posted Date
- 2005-07-15
- Lead Sponsor
- Anesiva, Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT00041925
- Locations
- 🇺🇸
Robert Packer Hospital, Sayre, Pennsylvania, United States
🇺🇸Vascular Specialists of Mobile, PC, Mobile, Alabama, United States
🇺🇸Springhill Memorial Hopsital, Mobile, Alabama, United States